Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Merus Labs' portfolio of well-established products are mainly marketed in Europe, and will drive the growth and diversification of Norgine’s specialty business in the region.
Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.